Kyung Im Kim and Ji-Won Kim are contributed equally to this work.
Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation
Article first published online: 8 DEC 2012
Copyright © 2012 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 88, Issue 2, pages 107–112, February 2013
How to Cite
Kim, K. I., Kim, J.-W., Lee, H. J., Kim, B.-S., Bang, S.-M., Kim, I., Oh, J. M., Yoon, S.-S., Lee, J. S., Park, S. and Kim, B. K. (2013), Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation. Am. J. Hematol., 88: 107–112. doi: 10.1002/ajh.23359
This study was presented at the annual meeting of American Society of Hematology (ASH), held in Orlando, Florida on December 7, 2010.
Conflict of interest: Nothing to report
- Issue published online: 24 JAN 2013
- Article first published online: 8 DEC 2012
- Accepted manuscript online: 17 NOV 2012 03:06AM EST
- Manuscript Accepted: 25 OCT 2012
- Manuscript Revised: 14 OCT 2012
- Manuscript Received: 16 JUL 2012
- Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea. Grant Number: A084783
- National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST). Grant Number: 2012-0000185
- Seoul National University Hospital Research Fund. Grant Number: 0320100080
Oral mucositis (OM) is one of the most common and debilitating complications in patients undergoing intensive chemotherapy followed by hematopoietic stem cell transplantation (HSCT). The aim of this study was to evaluate the efficacy and safety of recombinant human epidermal growth factor (rhEGF) oral spray for OM induced by intensive chemotherapy followed by HSCT. Patients were randomly assigned to either the rhEGF group or placebo group. The severity of OM and self-reported quality of life (QOL) were assessed daily. A total of 58 patients were analyzed. Baseline characteristics were similar between the two groups. The incidence of NCI grade ≥2 OM was higher in the rhEGF group (78.6% vs. 50%, P = 0.0496). However, the duration of OM in patients with NCI grade ≥2 tended to be shorter in the rhEGF group (8.5 days vs. 14.5 days, P = 0.262). The QOL analysis in patients with World Health Organization (WHO) grade ≥3 OM showed that rhEGF significantly reduced limitations in swallowing (P = 0.039) and drinking (P = 0.042). The duration of hospitalization (P = 0.047), administration of total parenteral nutrition (P = 0.012), and the usage of opioid analgesics (P = 0.018) were significantly shorter in the rhEGF group with WHO grade ≥3 OM. Adverse events were mild and similar between the two groups. In conclusion, this analysis showed that rhEGF did not reduce the incidence of NCI grade ≥2 OM. However, the patients with WHO grade ≥3 OM in the rhEGF group showed better results compared to the placebo group for several secondary endpoints. Am. J. Hematol. 88:107–112, 2013. © 2012 Wiley Periodicals, Inc.